Results 131 to 140 of about 1,721 (143)

Real-world characteristics and use patterns of patients treated with vericiguat: A nationwide longitudinal cohort study in Germany

European Journal of Clinical Pharmacology
Purpose Vericiguat reduced clinical endpoints in patients experiencing worsening heart failure in clinical trials, but its implementation outside trials is unclear.
Stefan Störk, Fabian Kerwagen
exaly   +2 more sources

Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA [PDF]

JACC: Heart Failure, 2023
Background: Vericiguat reduced the risk of cardiovascular death (CVD) or hospitalization for heart failure (HF) in patients with worsening HF and reduced left ventricular ejection fraction (LVEF).Objectives: The authors assessed the association of LVEF ...
Christopher R. deFilippi, Javed Butler, Armstrong, Paul W., Justin A. Ezekowitz, Adrian F. Hernandez, O'Connor, Christopher M., Hernandez, Adrian F., Cynthia M. Westerhout, Khan, Muhammad Shahzeb, Voors, Adriaan A., Diana Bonderman, Adriaan A. Voors, Butler, Javed, Paul W. Armstrong, Ezekowitz, Justin A., Westerhout, Cynthia M., Christopher M. O’Connor, Bonderman, Diana, Lam, Carolyn S.P., Lars H. Lund, Carolyn S.P. Lam, Robert O. Blaustein, Freitas, Cecilia, Lund, Lars H., Blaustein, Robert O., Cecilia Freitas, Yinggan Zheng, Muhammad Shahzeb Khan, Zheng, Yinggan, deFilippi, Christopher R.   +29 more
exaly   +2 more sources

Vericiguat Use in Patients with Heart Failure in Real-World Settings during the First Year after the Drug Authorization in Japan

Journal of Clinical Medicine
Background: Vericiguat was developed to treat patients with heart failure (HF). Currently, limited data are available to characterize vericiguat-treated patients in real-world clinical settings.
Alexander Michel, Tomomi Ide, Suguru Okami   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat.

Heart Failure, 2022
Justin Ezekowitz, Lothar Roessig
exaly  

Color based spectrophotometric determination of vericiguat using diazo coupling reaction; assisted computational calculations

Journal of Molecular Structure, 2023
Mohammed Gamal, Ahmed Hussien, Mohammed Ghoneim   +2 more
exaly  

Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis

Cardiovascular Drugs and Therapy, 2020
Kimon Stamatelopoulos, Georgios Georgiopoulos, Alberto Aimo   +2 more
exaly  

Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.

Annals of Pharmacotherapy, 2022
Nicole Campbell
exaly  

Evaluation of high-sensitivity C-reactive protein and uric acid in vericiguat-treated patients with heart failure with reduced ejection fraction

European Journal of Heart Failure, 2020
Javed Butler, Frank Kramer, Sanjiv J Shah   +2 more
exaly  

Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial

European Journal of Heart Failure, 2021
Javed Butler, Paul W Armstrong, Justin Ezekowitz   +2 more
exaly  

The soluble guanylate cyclase (sGC) stimulator vericiguat inhibits platelet activation and thrombosis

European Journal of Pharmacology
Huajie Xu, Jiaxiong Lin, Luning Zhou
exaly